Physician profile
Kyle J Eash
NPI 1790072395
$15,532.03
in general payments reported to CMS, 2019-2025
29 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $900 · 2021: $2,689 · 2022: $4,163 · 2023: $4,481 · 2024: $1,738 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,499 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,498.63 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,091.89 | 2020-2023 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $1,318.00 | 2020-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $1,315.41 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| E.R. Squibb & Sons, L.L.C. | $1,139.80 | 2022-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $1,135.85 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,011.61 | 2020-2024 | |
| Lilly USA, LLC | $907.66 | 2020-2023 | Olumiant, Taltz |
| Pfizer INC. | $798.94 | 2019-2023 | |
| Dermavant Sciences, INC. | $797.43 | 2022-2024 | Vtama |
| Incyte Corporation | $672.92 | 2021-2023 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $635.93 | 2021-2024 | Libtayo, Dupixent |
| Sun Pharmaceutical Industries INC. | $544.88 | 2020-2023 | Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $540.59 | 2020-2024 | Epsolay |
| Ucb, INC. | $503.87 | 2019-2025 | Bimzelx, Cimzia |
| Organogenesis INC. | $369.64 | 2024-2025 | Simplimax, Puraply Wound Matrix |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $357.84 | 2019-2023 | |
| Arcutis Biotherapeutics, INC. | $231.92 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.77 | 2024 | Spevigo |
| Kerecis Limited | $210.07 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Genentech USA, INC. | $188.33 | 2019-2021 | |
| Organon LLC | $120.19 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $108.95 | 2019-2021 | |
| Leo Pharma INC. | $105.03 | 2019-2025 | Adbry |
| Almirall LLC | $52.36 | 2019-2021 | |
| Mission Pharmacal Company | $41.34 | 2019-2020 | |
| Epi Health, LLC | $32.14 | 2021-2022 | |
| Journey Medical Corporation | $29.49 | 2023 | |
| Sandoz INC. | $20.83 | 2021 | |
| Fresenius Kabi USA, LLC | $17.35 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Eash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.